ARS Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $33,658 | $22,681 | $28,087 | $32,501 |
Gross Profit | 20,812 | 16,395 | 24,885 | 24,310 |
EBITDA | -59,444 | -57,780 | -40,987 | -48,799 |
EBIT | -59,860 | -58,177 | -41,404 | -51,151 |
Net Income | -62,339 | -60,618 | -41,324 | -51,151 |
Net Change In Cash | 33,658 | 22,681 | 28,087 | 32,501 |
Free Cash Flow | -60,927 | -44,946 | -43,485 | -47,244 |
Cash | 8,163 | 24,321 | 41,317 | 59,557 |
Basic Shares | 99,312 | 99,296 | 98,566 | 98,807 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $84,278 | $89,149 | $30 | $1,316 |
Gross Profit | 63,855 | 68,592 | 30 | -15,804 |
EBITDA | -167,412 | 8,365 | -54,292 | -34,363 |
EBIT | -168,779 | 8,286 | -54,365 | -34,682 |
Net Income | -171,298 | 7,998 | -54,365 | -34,682 |
Net Change In Cash | 84,278 | 89,149 | 30 | 1,316 |
Cost of Revenue | 150,455 | |||
Free Cash Flow | -171,205 | 12,985 | -59,441 | -40,277 |
Cash | 41,317 | 50,817 | 70,971 | 210,518 |
Basic Shares | 98,566 | 102,390 | 95,215 | 39,956 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.63 |
2026-03-31 | -$0.61 |
2025-12-31 | -$0.42 |
2025-09-30 | -$0.52 |